Investors



  • FOR INFORMATION ON
    REPORTING CHANGES AND
    REVISED REVENUE GUIDANCE click here.


  • FOR GIVEN IMAGING
    ACQUISITION INFORMATION, click here.


  • FOR 2013 INVESTOR DAY MATERIALS,
    click here.


  • For Pharmaceuticals
    spin-off information,
    click here.


  • For tax basis information
    due to the Mallinckrodt spin,
    click here.


News Release

Printer Friendly Version View printer-friendly version
<< Back
Covidien Announces FDA 510(k) Clearance of New LigaSure(TM) Instrument
New "small jaw device" puts multi-functionality in the surgeon's hands

BOULDER, Colo., Feb 16, 2011 (BUSINESS WIRE) --

Covidien (NYSE: COV), a leading global provider of healthcare products, today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the LigaSure(TM) Curved, Small Jaw, Open Sealer/Divider surgical instrument. The device is indicated for use in general surgery and will be available in the United States this quarter.

The LigaSure Curved, Small Jaw, Open Sealer/Divider, the newest addition to the LigaSure family of advanced surgical cutting/sealing devices, provides an integrated cutting mechanism independent of sealing, leaving the critical cutting decisions in the hands of the surgeon. Its multi-functional design also provides for blunt dissection and an enhanced, more efficient experience for the surgeon, especially in confined surgical spaces. A primary feature of this new LigaSure device is a low-temperature profile and minimal thermal spread to surrounding tissues.

The proven LigaSure technology, powered by the ForceTriadTM energy platform, provides surgeons with a continuous output of energy, monitoring the tissue and making real-time adjustments 3,333 times/second to seal vessel walls. LigaSure technology has been in use for 12 years, and is utilized in more than one million procedures around the world each year.

ABOUT COVIDIEN

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2010 revenue of $10.4 billion, Covidien has approximately 42,000 employees worldwide in more than 60 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.

SOURCE: Covidien

Covidien
Marta Newhart, 303-530-2300, ext. 7383
Vice President, Communications & Public Affairs
Energy-based Devices
marta.newhart@covidien.com
or
Bruce Farmer, 508-452-4372
Vice President
Public Relations
bruce.farmer@covidien.com
or
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com